These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14663012)

  • 1. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
    Schwarzschild MA; Xu K; Oztas E; Petzer JP; Castagnoli K; Castagnoli N; Chen JF
    Neurology; 2003 Dec; 61(11 Suppl 6):S55-61. PubMed ID: 14663012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
    Ikeda K; Kurokawa M; Aoyama S; Kuwana Y
    J Neurochem; 2002 Jan; 80(2):262-70. PubMed ID: 11902116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
    Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
    Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    Chen JF; Xu K; Petzer JP; Staal R; Xu YH; Beilstein M; Sonsalla PK; Castagnoli K; Castagnoli N; Schwarzschild MA
    J Neurosci; 2001 May; 21(10):RC143. PubMed ID: 11319241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
    Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
    Chen JF; Sonsalla PK; Pedata F; Melani A; Domenici MR; Popoli P; Geiger J; Lopes LV; de Mendonça A
    Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
    Chase TN; Bibbiani F; Bara-Jimenez W; Dimitrova T; Oh-Lee JD
    Neurology; 2003 Dec; 61(11 Suppl 6):S107-11. PubMed ID: 14663022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the adenosine A
    Zhao Y; Zhou YG; Chen JF
    Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
    Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
    J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
    J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
    Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
    Schwarzschild MA; Chen JF; Ascherio A
    Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A2A receptors in neuroprotection of dopaminergic neurons.
    Pedata F; Pugliese AM; Melani A; Gianfriddo M
    Neurology; 2003 Dec; 61(11 Suppl 6):S49-50. PubMed ID: 14663010
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
    Castagnoli N; Petzer JP; Steyn S; Castagnoli K; Chen JF; Schwarzschild MA; Van der Schyf CJ
    Neurology; 2003 Dec; 61(11 Suppl 6):S62-8. PubMed ID: 14663013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.